Table 1.
Anti-BCMA CAR-T cell products in clinical trials included EMM patients.
| No. of EMMpatients | Name | Clinical trial information | Major response | Reference |
|---|---|---|---|---|
| 1 (16) | Anti-BCMA CAR-T cell therapy | NCT02215967 | the ORR of EMM is 100% (1/1), with 1 (100%) VGPR (at 51 weeks); the ORR of non-EMM is 80% (12/15) with 2 (13%) sCR/CR and 9 (60%) ≥VGPR. |
Brudno, J N et al. (13) |
| 9 (33) | bb2121 | Phase Ib NCT02658929 |
the ORR of EMM is 89% (8/9), with 4 (44%) sCR/CR and 6 (66%) ≥ VGPR; ORR of non-EMM is 83% (20/24) with 11 (33%) sCR/CR and 18 (75%) ≥VGPR. |
Raje, Noopur et al. (15) |
| 5 (17) | LCAR-B38M | Phase I/II NCT03090659 |
the ORR of EMM is 80% (4/5), with 3 (60%) sCR/CR and 4 (80%)≥ VGPR; ORR of non-EMM is 92% (11/12) with 9 (75%) sCR/CR and 11 (92%) ≥VGPR. |
Xu, Jie et al. (11) |
| 7 (25) | Anti-BCMA CAR-T cell therapy | Phase I NCT02546167 |
the ORR of EMM is 57% (4/7), with 2 (29%) sCR/CR and 4 (57%)≥ VGPR. | Cohen, Adam D et al. (16) |
| 50 (128) | ide-cel (bb2121) | Phase II NCT03361748 |
CR rate: non-EMM>EMM (no accurate values); ORR: non-EMM>EMM (no accurate values). |
Munshi, N C et al. (10) |
| 7 (23) | CT103A | Phase I ChiCTR1800018137 |
the ORR of EMM was 100% (7/7), with 2 (29%) sCR/CR and 5 (71%) ≥ VGPR; the ORR of non-EMM was 100% (16/16), with 13 (81%) sCR/CR and 14 (88%) ≥ VGPR. | Wang, D et al. (14) |
| 18 (38) | Murine BCMA CAR-T cell therapy | Phase I ChiCTR-OPC-16009113 |
the ORR of EMM was 77.78% (14/18), with 7 (39%) sCR/CR and 10 (56%) ≥ VGPR; the ORR of non-EMM was 90% (18/20), with 9 (45%) sCR/CR and 11 (55%) ≥ VGPR. | Li, C et al. (12) |
EMM, extramedullary myeloma; BCMA, B-cell maturation antigen; CAR, chimeric antigen receptor; ORR, objective response rate; OS, overall survival; sCR, stringent complete response; VGPR, very good partial response.